Kura Oncology (KURA) begins KOMZIFTI sales and posts wider 2025 loss
Rhea-AI Filing Summary
Kura Oncology reported its first commercial revenue from KOMZIFTI (ziftomenib) alongside fourth quarter and full year 2025 results. KOMZIFTI, the first approved once-daily oral menin inhibitor for relapsed or refractory NPM1‑mutated AML, generated $2.1 million in net product revenue in Q4 2025 from about five weeks of sales.
Total Q4 2025 revenue was $17.3 million, driven by $15.2 million of collaboration revenue, down from $53.9 million a year earlier. Higher investment in development and commercialization increased R&D expenses to $64.4 million and SG&A to $39.1 million, resulting in a Q4 net loss of $81.0 million, compared with a $19.2 million loss in Q4 2024.
For full year 2025, net loss was $278.7 million. The company ended 2025 with $667.2 million in cash, cash equivalents and short-term investments and expects this, together with $180 million in anticipated collaboration payments, to fund its ziftomenib AML program through first topline Phase 3 KOMET‑017 frontline results, anticipated in 2028, and to support its broader pipeline into the fourth quarter of 2027.
Positive
- First commercial revenue and strong cash runway: KOMZIFTI’s launch generated $2.1 million in Q4 2025 net product revenue, and Kura ended 2025 with $667.2 million in cash plus $180 million in anticipated collaboration payments, which it believes will fund the ziftomenib AML program through first topline Phase 3 KOMET‑017 results.
Negative
- Substantially higher losses driven by spending: Net loss widened to $81.0 million in Q4 2025 from $19.2 million a year earlier, and to $278.7 million for full year 2025 from $174.0 million in 2024, reflecting sharply higher R&D and SG&A expenses.
Insights
First KOMZIFTI sales begin while Kura spends heavily to build a broader AML and solid tumor franchise.
Kura Oncology has transitioned to a commercial-stage company with KOMZIFTI, recording
Q4 2025 total revenue was
Liquidity appears robust, with
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices)
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 5, 2026, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2025 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1.
The information contained in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press release dated March 5, 2026 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
KURA ONCOLOGY, INC. |
|
|
|
|
|
Date: March 5, 2026 |
|
By: |
/s/ Teresa Bair |
|
|
|
Teresa Bair |
|
|
|
Chief Legal Officer |
Exhibit 99.1
Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions –
– Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients –
– Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI –
– FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma –
– Multiple 2026 clinical data milestones expected across AML and solid tumor programs –
– Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program to first topline Phase 3 results in KOMET-017 –
– Management to host webcast and conference call today at 8:00 a.m. ET –
SAN DIEGO, March 5, 2026 – Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported fourth quarter and full year 2025 financial results and provided a corporate update.
“We are encouraged by the early launch trajectory of KOMZIFTI and the positive feedback from physicians, pharmacists and payers on its differentiated clinical profile,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “With a compelling combination of efficacy, safety, compatibility, and simplicity, we believe KOMZIFTI is well positioned to lead in R/R NPM1-mutated AML. In 2026, we expect multiple clinical milestones in the combination and frontline settings that could significantly broaden the opportunity for ziftomenib across the AML treatment continuum. In addition, our solid tumor programs, including ziftomenib in gastrointestinal tumors and darlifarnib in both renal cell carcinoma and KRASG12C-mutated solid tumors, continue to advance, representing a potential addressable population of more than 200,000 patients. Importantly, our strong balance sheet, bolstered by anticipated
collaboration milestones, provides the capital required to reach key value-inflecting frontline Phase 3 data and advance our next wave of novel therapies.”
2025 Highlights and Recent Developments
KOMZIFTI Commercial Launch
Advancing Ziftomenib Across the AML Treatment Continuum
2
Solid Tumor Pipeline Progress
2026 Strategic Priorities and Anticipated Milestones
Kura expects 2026 to be a data-rich year with multiple potential value inflection points:
KOMZIFTI Commercial Execution
Ziftomenib – Development in Frontline AML
Ziftomenib – Development in R/R AML
Ziftomenib and Menin Inhibition – Expansion into Solid Tumors
3
Darlifarnib
KO-7246 (Next-Generation Menin Inhibitor)
Fourth Quarter 2025 Financial Results
As of December 31, 2025, Kura had $667.2 million in cash, cash equivalents and short-term investments, compared to $727.4 million as of December 31, 2024.
The Company believes that its cash, cash equivalents and short-term investments as of December 31, 2025, will be sufficient to fund its current operating plan into the fourth quarter of 2027. When combined with the anticipated $180 million in payments under the collaboration agreement with Kyowa Kirin, these resources are expected to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 frontline trial, anticipated in 2028.
Conference Call and Webcast
Kura’s management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT today, March 5, 2026, to discuss financial results and to provide a corporate update.
4
A live webcast and archived replay of the event will be available here or online from the Investors section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura’s performance in 2026; the commercial potential of KOMZIFTI; KOMZIFTI’s potential long-term value; KOMZIFTI’s potential market leadership in R/R NPM1-m AML; Kura’s research, preclinical and clinical development activities; plans and projected timelines for ziftomenib, darlifarnib and preclinical assets; the expected timing and presentation of results and data from clinical trials; the strength of Kura’s balance sheet and Kura’s anticipated cash runway. Factors that may cause actual results to differ materially include risks associated with market competition, market acceptance and commercialization of KOMZIFTI; risks associated with the conduct of preclinical studies and clinical trials; risks that Kura’s actual future financial and operating results may differ from its expectations or goals; the risk that Kura’s product candidates may not receive regulatory approval; the potential for KOMZIFTI or Kura’s product candidates to have unexpected adverse side effects; the risk that Kura may not be able to obtain additional financing; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the
5
date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
FLT3, Fms-like tyrosine kinase 3 gene; KMT2A, lysine methyltransferase 2A gene; NPM1, nucleophosmin 1 gene; ITD, Internal Random Duplication; KRAS, Kirsten Rat Sarcoma Virus oncogene homolog.
KURA ONCOLOGY, INC. |
|
|||||||||||||||
Statements of Operations Data |
|
|||||||||||||||
(unaudited) |
|
|||||||||||||||
(in thousands, except per share data) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue, net |
|
$ |
2,132 |
|
|
$ |
— |
|
|
$ |
2,132 |
|
|
$ |
— |
|
Collaboration revenue |
|
|
15,204 |
|
|
|
53,883 |
|
|
|
65,350 |
|
|
|
53,883 |
|
Total revenue |
|
|
17,336 |
|
|
|
53,883 |
|
|
|
67,482 |
|
|
|
53,883 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of product sales |
|
|
57 |
|
|
|
— |
|
|
|
57 |
|
|
|
— |
|
Research and development |
|
|
64,408 |
|
|
|
52,267 |
|
|
|
251,074 |
|
|
|
169,967 |
|
Selling, general and administrative |
|
|
39,139 |
|
|
|
24,071 |
|
|
|
119,982 |
|
|
|
77,111 |
|
Total operating expenses |
|
|
103,604 |
|
|
|
76,338 |
|
|
|
371,113 |
|
|
|
247,078 |
|
Other income, net |
|
|
5,340 |
|
|
|
5,256 |
|
|
|
25,262 |
|
|
|
21,230 |
|
Income tax expense |
|
|
71 |
|
|
|
2,018 |
|
|
|
297 |
|
|
|
2,018 |
|
Net loss |
|
$ |
(80,999 |
) |
|
$ |
(19,217 |
) |
|
$ |
(278,666 |
) |
|
$ |
(173,983 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.92 |
) |
|
$ |
(0.22 |
) |
|
$ |
(3.18 |
) |
|
$ |
(2.02 |
) |
Weighted average number of shares used in computing net loss per share, basic and diluted |
|
|
88,050 |
|
|
|
87,136 |
|
|
|
87,676 |
|
|
|
86,161 |
|
KURA ONCOLOGY, INC. |
|
|||||||
Balance Sheet Data |
|
|||||||
(unaudited) |
|
|||||||
(in thousands) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
December 31, |
|
|
December 31, |
|
||
|
|
2025 |
|
|
2024 |
|
||
Cash, cash equivalents and short-term investments |
|
$ |
667,240 |
|
|
$ |
727,395 |
|
Working capital |
|
|
591,689 |
|
|
|
666,117 |
|
Total assets |
|
|
738,363 |
|
|
|
760,159 |
|
Long-term liabilities |
|
|
447,254 |
|
|
|
267,807 |
|
Accumulated deficit |
|
|
(1,174,088 |
) |
|
|
(895,422 |
) |
Stockholders’ equity |
|
|
174,135 |
|
|
|
413,640 |
|
6
About KOMZIFTI™ (ziftomenib)
KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
Ziftomenib is in development for the frontline treatment of AML harboring NPM1 mutations, KMT2A translocations and FLT3 mutations, with the potential to be combined with approved therapies and benefit a broad spectrum of patients earlier in their disease course.
IMPORTANT SAFETY INFORMATION FOR KOMZIFTI FROM THE U.S. PRESCRIBING INFORMATION
Boxed WARNING: DIFFERENTIATION SYNDROME
Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI, and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement.
WARNINGS AND PRECAUTIONS
Differentiation Syndrome
KOMZIFTI can cause fatal or life-threatening differentiation syndrome (DS). DS is associated with rapid proliferation and differentiation of myeloid cells. Symptoms of DS, including those seen in patients treated with KOMZIFTI, may include fever, hypoxia, joint pain, hypotension, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, acute kidney injury, and rashes.
In the clinical trial, DS occurred in 29 (26%) of 112 patients with R/R AML with an NPM1 mutation who were treated with KOMZIFTI at the recommended dosage. DS was Grade 3 in 13% and fatal in two patients. In broader evaluation of all patients with any genetic form of AML treated with KOMZIFTI monotherapy in clinical trials, DS occurred in 25% of patients. Four fatal cases of DS occurred out of 39 patients with KMT2A-rearranged AML treated with KOMZIFTI. KOMZIFTI is not approved for use in patients with KMT2A-rearranged AML.
7
In the 112 patients with an NPM1 mutation, DS was observed with and without concomitant hyperleukocytosis, in as early as 3 days and up to 46 days after KOMZIFTI initiation. The median time to onset was 15 days. Two patients experienced more than one DS event. Treatment was interrupted and resumed in 15 (13%) patients, while it was permanently discontinued in 2 (2%) patients.
Prior to starting treatment with KOMZIFTI, reduce the WBC counts to less than 25 x 10⁹/L. If DS is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring. Resume treatment with KOMZIFTI at the same dose level when signs and symptoms improve and are Grade 2 or lower. Taper corticosteroids over a minimum of 3 days after adequate control or resolution of symptoms. Symptoms of DS may recur with premature discontinuation of corticosteroid treatment.
QTc Interval Prolongation
KOMZIFTI can cause QTc interval prolongation. In the clinical trial, QTc interval prolongation was reported as an adverse reaction in 12% of 112 patients treated with KOMZIFTI at the recommended dosage for R/R AML with an NPM1 mutation. QTc interval prolongation was Grade 3 in 8% of patients. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 9% of patients, and the increase from baseline QTcF was greater than 60 msec in 12% of patients. KOMZIFTI dose reduction was required for 1% of patients due to QTc interval prolongation. QTc prolongation occurred in 14% of the 42 patients less than 65 years of age and in 10% of the 70 patients 65 years of age or older.
Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with KOMZIFTI. Perform an ECG prior to initiation of treatment with KOMZIFTI, and do not initiate KOMZIFTI in patients with QTcF > 480 msec. Perform an ECG at least once weekly for the first four weeks on treatment, and at least monthly thereafter. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms (Grade 3). In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of KOMZIFTI with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsades de Pointes, other serious arrhythmias, and sudden death.
8
Embryo-Fetal Toxicity
Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 3 months after the last dose.
ADVERSE REACTIONS
Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).
Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. Adverse reactions that required dose interruption in ≥ 2% of patients included infection without an identified pathogen (15%), differentiation syndrome (13%), febrile neutropenia (5%), pyrexia (4%), electrocardiogram QT prolonged (4%), leukocytosis (4%), bacterial infection (3%), cardiac failure (2%), cholecystitis (2%), diarrhea (2%), pruritus (2%), and thrombosis (2%). Dose reduction of KOMZIFTI due to an adverse reaction occurred in 4% of patients. Permanent discontinuation of KOMZIFTI due to an adverse reaction occurred in 21% of patients. Adverse reactions that required permanent discontinuation of KOMZIFTI in ≥ 2% of patients were infection without an identified pathogen (8%), bacterial infection (4%), cardiac arrest (2%), and differentiation syndrome (2%).
Most common (≥ 20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased (53%), infection without an identified pathogen (52%), potassium decreased (52%), albumin decreased (51%), alanine aminotransferase increased (50%), sodium decreased (49%), creatinine increased (45%), alkaline phosphatase increased (41%), hemorrhage (38%), diarrhea (36%), nausea (35%), fatigue (34%), edema (30%), bacterial infection (28%), musculoskeletal pain (28%), bilirubin increased (27%), potassium increased (26%), differentiation syndrome (26%), pruritus (23%), febrile neutropenia (22%), and transaminases increased (21%).
9
DRUG INTERACTIONS
Drug interactions may occur when KOMZIFTI is concomitantly used with:
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to starting KOMZIFTI.
Lactation: Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with KOMZIFTI and for 2 weeks after the last dose.
Infertility: Based on findings in animals, KOMZIFTI may impair fertility in females and males of reproductive potential.
Please see full Prescribing Information, including Boxed WARNING.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
10
FAQ
How much revenue did Kura Oncology (KURA) generate from KOMZIFTI in Q4 2025?
What were Kura Oncology’s key financial results for Q4 2025?
What cash position and runway does Kura Oncology (KURA) report at year-end 2025?
How did Kura Oncology’s expenses change in Q4 2025 versus Q4 2024?
What is the status of Kura Oncology’s KOMET‑017 Phase 3 trials for ziftomenib?
How long does Kura Oncology expect funding for its ziftomenib AML program to last?
Filing Exhibits & Attachments
2 documentsPress Releases
